Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Pancreatitis

Free Subscription Articles published in Gut Retrieve available abstracts of 91 articles: HTML format

Single Articles

January 2026
1. ESPOSITO I, Haeberle L, Luchini C
   From IPMN to invasive pancreatic cancer: new spatial insights.
   Gut. 2026 Jan 28:gutjnl-2025-337622. doi: 10.1136/gutjnl-2025-337622.
   PubMed    
   
   
   
2. ZENG L, Liu S, Peng X, Xue C, et al
   NSUN6 deficiency drives immune suppression in pancreatic cancer via the KDM5A-CCL2-macrophage axis.
   Gut. 2026 Jan 22:gutjnl-2025-336541. doi: 10.1136/gutjnl-2025-336541.
   PubMed     Abstract available
   
   
   
3. SHI J, Wang X, Tang Y, Meng S, et al
   LY6D identifies persistent stem-like cells driving pancreatic tumourigenesis.
   Gut. 2026 Jan 16:gutjnl-2025-336460. doi: 10.1136/gutjnl-2025-336460.
   PubMed     Abstract available
   
   
   
4. CHEN K, Ma Y, Huang L, Wu P, et al
   Complement-secreting CAFs are associated with better prognosis in pancreatic cancer: single-cell multiomics.
   Gut. 2026 Jan 13:gutjnl-2025-335683. doi: 10.1136/gutjnl-2025-335683.
   PubMed     Abstract available
   
   
   
5. LIU J, Hou X, Li L, Bai W, et al
   KRAS mutation-driven O-GlcNAcylation of CLDN18.2 enhances the progression of pancreatic cancer and reduces the efficacy of CLDN18.2-targeted therapy.
   Gut. 2026 Jan 9:gutjnl-2025-336277. doi: 10.1136/gutjnl-2025-336277.
   PubMed     Abstract available
   
   
   
6. ZHENG Y, Scheers I, Sandor M, Yi G, et al
   Mutations of Gly277 in CPA1-related chronic pancreatitis: clinical clues for misfolding aetiology.
   Gut. 2026 Jan 6:gutjnl-2025-337733. doi: 10.1136/gutjnl-2025-337733.
   PubMed    
   
   
   
7. WU D, Zhu C, Pan H, Xu H, et al
   Integrated screens reveal that guanine nucleotide depletion, which is irreversible via targeting IMPDH2, inhibits pancreatic cancer and potentiates KRAS inhibition.
   Gut. 2026 Jan 6:gutjnl-2025-336235. doi: 10.1136/gutjnl-2025-336235.
   PubMed     Abstract available
   
   
   
8. GUILABERT L, Cardenas-Jaen K, Vaillo-Rocamora A, Ruiz-Rebollo ML, et al
   Simvastatin in the prevention of recurrent pancreatitis: a triple-blinded randomised clinical trial (the SIMBA trial).
   Gut. 2026 Jan 2:gutjnl-2025-337154. doi: 10.1136/gutjnl-2025-337154.
   PubMed     Abstract available
   
   
   December 2025
9. LATIF MU, Liu X, Bockelmann A, Huhnold L, et al
   GSK3beta(high)/NFATc1(high) subtype targeting overcomes therapy resistance in pancreatic cancer through transcriptional induction of homologous recombination repair.
   Gut. 2025 Dec 31:gutjnl-2025-336227. doi: 10.1136/gutjnl-2025-336227.
   PubMed     Abstract available
   
   
   
10. INAMDAR TV, Krannich F, Hesselbarth N, Verma A, et al
    Hereditary chronic pancreatitis induced plasticity cooperates with mutant Kras in early pancreatic carcinogenesis.
    Gut. 2025 Dec 19:gutjnl-2025-335947. doi: 10.1136/gutjnl-2025-335947.
    PubMed     Abstract available
    
    
    
11. CUI M, Mo S, Bai J, Javed AA, et al
    Spatial transcriptomics defines the molecular progression, invasion and immune landscape of IPMN and IPMN-derived pancreatic cancer.
    Gut. 2025 Dec 11:gutjnl-2025-336117. doi: 10.1136/gutjnl-2025-336117.
    PubMed     Abstract available
    
    
    November 2025
12. AMMER-HERRMENAU C, Meier R, Antweiler KL, Asendorf T, et al
    Gut microbiota predict development of postdischarge diabetes mellitus in acute pancreatitis.
    Gut. 2025 Nov 26:gutjnl-2025-336715. doi: 10.1136/gutjnl-2025-336715.
    PubMed     Abstract available
    
    
    
13. KUSAY Y, Wu D, De Sousa SM, Drogemuller CJ, et al
    Evaluating NGS variant callers in a challenging genomic context with a focus on the PRSS1-PRSS2 locus for hereditary pancreatitis.
    Gut. 2025 Nov 17:gutjnl-2025-336988. doi: 10.1136/gutjnl-2025-336988.
    PubMed    
    
    
    
14. CHARI ST
    Diabetes and pancreatic cancer: a complex and confounding interplay.
    Gut. 2025 Nov 12:gutjnl-2025-336806. doi: 10.1136/gutjnl-2025-336806.
    PubMed    
    
    
    October 2025
15. LIN J, Cai W, Kattakayam A, He W, et al
    Pharmacological trials of early intervention in predicted severe acute pancreatitis: implications for therapeutic window and core outcome set.
    Gut. 2025 Oct 29:gutjnl-2025-336884. doi: 10.1136/gutjnl-2025-336884.
    PubMed    
    
    
    
16. HAMADA T, Saito T, Michihata N, Yasunaga H, et al
    Response to: 'Lumen-apposing metal stents for pancreatic fluid collections: has advancing technology encouraged overreach?' by Besim Fazil et al.
    Gut. 2025 Oct 15:gutjnl-2025-337023. doi: 10.1136/gutjnl-2025-337023.
    PubMed    
    
    
    
17. ZHONG J, O'Brien A, Patel MB, Eiser D, et al
    Large-scale multiomic analysis identifies non-coding somatic driver mutations and nominates ZFP36L2 as a driver gene for pancreatic ductal adenocarcinoma.
    Gut. 2025 Oct 8:gutjnl-2025-335152. doi: 10.1136/gutjnl-2025-335152.
    PubMed     Abstract available
    
    
    September 2025
18. TAN JT, Mao X, Lui DT, Li C, et al
    Glycaemic control is a modifiable risk factor for pancreatic cancer development in patients with diabetes: a population-based cohort study.
    Gut. 2025 Sep 18:gutjnl-2025-335837. doi: 10.1136/gutjnl-2025-335837.
    PubMed     Abstract available
    
    
    
19. AGARGUN BF, Cavus B, Cifcibasi Ormeci A, Demir K, et al
    Lumen-apposing metal stents for pancreatic fluid collections: has advancing technology encouraged over-reach?
    Gut. 2025 Sep 18:gutjnl-2025-336668. doi: 10.1136/gutjnl-2025-336668.
    PubMed    
    
    
    August 2025
20. PISEDDU I, Mayerle J, Mahajan UM, Boehmer DFR, et al
    The dual role of IgG4 in immunity: bridging pathophysiology and therapeutic applications.
    Gut. 2025;74:1528-1538.
    PubMed     Abstract available
    
    
    July 2025
21. HAMADA T, Michihata N, Saito T, Kimura Y, et al
    Real-world impact of implementing lumen-apposing metal stents for pancreatic fluid collections: a nationwide Japanese study.
    Gut. 2025 Jul 30:gutjnl-2025-335067. doi: 10.1136/gutjnl-2025-335067.
    PubMed     Abstract available
    
    
    
22. 
    Correction: pancreatic STAT5 activation promotes KrasG12D-induced and inflammation-induced acinar-to-ductal metaplasia and pancreatic cancer.
    Gut. 2025 Jul 2:gutjnl-2024-332225corr1. doi: 10.1136/gutjnl-2024-332225.
    PubMed    
    
    
    June 2025
23. HARLE A, Kleger A
    Early metabolic fate commitment in pancreatic neoplastic precursors.
    Gut. 2025 Jun 4:gutjnl-2025-335439. doi: 10.1136/gutjnl-2025-335439.
    PubMed    
    
    
    
24. YANG J, Yu X, Xiao M, Xu H, et al
    Histone lactylation-driven feedback loop modulates cholesterol-linked immunosuppression in pancreatic cancer.
    Gut. 2025 Jun 4:gutjnl-2024-334361. doi: 10.1136/gutjnl-2024-334361.
    PubMed     Abstract available
    
    
    April 2025
25. HUANG L, Feng Z, Yang W, Zhu Y, et al
    Parecoxib sequential with imrecoxib for occurrence and remission of severe acute pancreatitis: a multicentre, double-blind, randomised, placebo-controlled trial.
    Gut. 2025 Apr 29:gutjnl-2024-334038. doi: 10.1136/gutjnl-2024-334038.
    PubMed     Abstract available
    
    
    
26. CHEN Y, Ballaro R, Sans M, Thege FI, et al
    Long-chain sulfatide enrichment is an actionable metabolic vulnerability in intraductal papillary mucinous neoplasm (IPMN)-associated pancreatic cancers.
    Gut. 2025 Apr 23:gutjnl-2025-335220. doi: 10.1136/gutjnl-2025-335220.
    PubMed     Abstract available
    
    
    
27. BODAS C, Felipe I, Chanez B, Lafarga M, et al
    A Common CTRB misfolding variant associated with pancreatic cancer risk causes ER stress and inflammation in mice.
    Gut. 2025 Apr 19:gutjnl-2024-333406. doi: 10.1136/gutjnl-2024-333406.
    PubMed     Abstract available
    
    
    
28. WU H, Gao SZ, Yin LD, Wang YH, et al
    Germline mutations and pancreatic cancer risk in chronic pancreatitis.
    Gut. 2025 Apr 5:gutjnl-2024-334277. doi: 10.1136/gutjnl-2024-334277.
    PubMed    
    
    
    March 2025
29. PERRI G, Marchegiani G
    Introducing 'borderline observable' intraductal papillary mucinous neoplasms: between pancreatic cancer risk and discontinuation of extended surveillance.
    Gut. 2025 Mar 26:gutjnl-2025-334807. doi: 10.1136/gutjnl-2025-334807.
    PubMed    
    
    
    
30. SUN X, Cai W, Li H, Gao C, et al
    Endothelial-like cancer-associated fibroblasts facilitate pancreatic cancer metastasis via vasculogenic mimicry and paracrine signalling.
    Gut. 2025 Mar 23:gutjnl-2024-333638. doi: 10.1136/gutjnl-2024-333638.
    PubMed     Abstract available
    
    
    
31. COTE GA
    Rectal non-steroidal anti-inflammatory drugs and post-ERCP pancreatitis: it is time for the next chapter in prophylaxis.
    Gut. 2025 Mar 23:gutjnl-2025-334989. doi: 10.1136/gutjnl-2025-334989.
    PubMed    
    
    
    
32. KANG X, Xia M, Wang J, Wang X, et al
    Rectal diclofenac versus indomethacin for prevention of post-ERCP pancreatitis (DIPPP): a multicentre, double-blind, randomised, controlled trial.
    Gut. 2025 Mar 20:gutjnl-2024-334466. doi: 10.1136/gutjnl-2024-334466.
    PubMed     Abstract available
    
    
    January 2025
33. EKSTROM TL, Rosok RM, Abdelrahman AM, Parassiadis C, et al
    Glucocorticoid receptor suppresses GATA6-mediated RNA polymerase II pause release to modulate classical subtype identity in pancreatic cancer.
    Gut. 2025 Jan 30:gutjnl-2024-334374. doi: 10.1136/gutjnl-2024-334374.
    PubMed     Abstract available
    
    
    
34. HAMADA T, Oyama H, Nevo D, Tange S, et al
    Risk factors for pancreatic cancer in individuals with intraductal papillary mucinous neoplasms and no high-risk stigmata during up to 5 years of surveillance: a prospective longitudinal cohort study.
    Gut. 2025 Jan 27:gutjnl-2024-333259. doi: 10.1136/gutjnl-2024-333259.
    PubMed     Abstract available
    
    
    
35. ZHANG S, Deng S, Liu J, Liu S, et al
    Targeting MXD1 sensitises pancreatic cancer to trametinib.
    Gut. 2025 Jan 16:gutjnl-2024-333408. doi: 10.1136/gutjnl-2024-333408.
    PubMed     Abstract available
    
    
    
36. RUSSELL SN, Demetriou C, Valenzano G, Evans A, et al
    Induction of macrophage efferocytosis in pancreatic cancer via PI3Kgamma inhibition and radiotherapy promotes tumour control.
    Gut. 2025 Jan 9:gutjnl-2024-333492. doi: 10.1136/gutjnl-2024-333492.
    PubMed     Abstract available
    
    
    
37. TAN JT, Mao X, Cheng HM, Seto WK, et al
    Aspirin is associated with lower risk of pancreatic cancer and cancer-related mortality in patients with diabetes mellitus.
    Gut. 2025 Jan 2:gutjnl-2024-333329. doi: 10.1136/gutjnl-2024-333329.
    PubMed     Abstract available
    
    
    December 2024
38. MASSON E, Vedie AL, Maire F, Godet T, et al
    Frequency of de novo PRSS1 pathogenic variants in a French cohort of idiopathic pancreatitis.
    Gut. 2024 Dec 31:gutjnl-2024-333908. doi: 10.1136/gutjnl-2024-333908.
    PubMed    
    
    
    
39. HOLLENBACH M, Heise C, Abou-Ali E, Gulla A, et al
    Endoscopic papillectomy versus surgical ampullectomy for adenomas and early cancers of the papilla: a retrospective Pancreas2000/European Pancreatic Club analysis.
    Gut. 2024 Dec 12:gutjnl-2022-327996. doi: 10.1136/gutjnl-2022-327996.
    PubMed     Abstract available
    
    
    
40. 
    Correction: The Peptidoglycan Recognition Protein 1 confers immune evasive properties on pancreatic cancer stem cells.
    Gut. 2024;74:e11.
    PubMed    
    
    
    November 2024
41. XIAO M, Tang R, Pan H, Yang J, et al
    TPX2 serves as a novel target for expanding the utility of PARPi in pancreatic cancer through conferring synthetic lethality.
    Gut. 2024 Nov 5:gutjnl-2024-332782. doi: 10.1136/gutjnl-2024-332782.
    PubMed     Abstract available
    
    
    October 2024
42. ESPINET E, Natoli G
    Leveraging the tug-of-war with genomic retroelements to enhance immunotherapy of pancreatic cancer.
    Gut. 2024 Oct 22:gutjnl-2024-333702. doi: 10.1136/gutjnl-2024-333702.
    PubMed    
    
    
    
43. ONNEKINK AM, Gorris M, Bekkali NL, Bos P, et al
    Endoscopic sphincterotomy to prevent post-ERCP pancreatitis after self-expandable metal stent placement for distal malignant biliary obstruction (SPHINX): a multicentre, randomised controlled trial.
    Gut. 2024 Oct 10:gutjnl-2024-332695. doi: 10.1136/gutjnl-2024-332695.
    PubMed     Abstract available
    
    
    September 2024
44. SANDOR M, Scheers I, Masamune A, Witt H, et al
    AlphaMissense versus laboratory-based pathogenicity prediction of 13 novel missense CPA1 variants from pancreatitis cases.
    Gut. 2024 Sep 10:gutjnl-2024-333697. doi: 10.1136/gutjnl-2024-333697.
    PubMed    
    
    
    
45. 
    Correction: Macrophages direct cancer cells through a LOXL2-mediated metastatic cascade in pancreatic ductal adenocarcinoma.
    Gut. 2024;73:e21.
    PubMed    
    
    
    
46. COTE GA, Elmunzer BJ, Nitchie H, Kwon RS, et al
    Sphincterotomy for biliary sphincter of Oddi disorder and idiopathic acute recurrent pancreatitis: the RESPOnD longitudinal cohort.
    Gut. 2024 Sep 7:gutjnl-2024-332686. doi: 10.1136/gutjnl-2024-332686.
    PubMed     Abstract available
    
    
    August 2024
47. TANG Y, Tang S, Yang W, Zhang Z, et al
    MED12 loss activates endogenous retroelements to sensitise immunotherapy in pancreatic cancer.
    Gut. 2024 Aug 31:gutjnl-2024-332350. doi: 10.1136/gutjnl-2024-332350.
    PubMed     Abstract available
    
    
    
48. ZHOU T, Hou X, Yan J, Li L, et al
    CD64(+) fibroblast-targeted vilanterol and a STING agonist augment CLDN18.2 BiTEs efficacy against pancreatic cancer by reducing desmoplasia and enriching stem-like CD8(+) T cells.
    Gut. 2024 Aug 30:gutjnl-2024-332371. doi: 10.1136/gutjnl-2024-332371.
    PubMed     Abstract available
    
    
    July 2024
49. ZUO X, Wang L, Liu Y, Wang H, et al
    Dysregulated KLF4 expression plays a pivotal role in the pathogenesis of pancreatic intraductal papillary mucinous neoplasms.
    Gut. 2024 Jul 5:gutjnl-2024-332255. doi: 10.1136/gutjnl-2024-332255.
    PubMed    
    
    
    
50. KAMAR N, Marion O, Abravanel F, Esposito L, et al
    Porcine-derived pancreatic enzyme replacement therapy: a cause of hepatitis E virus transmission?
    Gut. 2024 Jul 2:gutjnl-2024-332744. doi: 10.1136/gutjnl-2024-332744.
    PubMed    
    
    
    
51. LIN Y, Pu S, Wang J, Wan Y, et al
    Pancreatic STAT5 activation promotes Kras(G12D)-induced and inflammation-induced acinar-to-ductal metaplasia and pancreatic cancer.
    Gut. 2024 Jul 1:gutjnl-2024-332225. doi: 10.1136/gutjnl-2024-332225.
    PubMed     Abstract available
    
    
    June 2024
52. SHEN F, Zhao H, Deng M, Tu M, et al
    Familial pancreatitis associated with a splice-site variant in CPA1.
    Gut. 2024 Jun 18:gutjnl-2024-332845. doi: 10.1136/gutjnl-2024-332845.
    PubMed    
    
    
    
53. ZHOU J, Liu K, Pan Q
    Porcine-derived pancreatic enzyme replacement therapy linking to chronic hepatitis E: broad implications.
    Gut. 2024 Jun 12:gutjnl-2024-332975. doi: 10.1136/gutjnl-2024-332975.
    PubMed    
    
    
    
54. BRICHKINA A, Ems M, Suezov R, Singh R, et al
    DYRK1B blockade promotes tumoricidal macrophage activity in pancreatic cancer.
    Gut. 2024 Jun 4:gutjnl-2023-331854. doi: 10.1136/gutjnl-2023-331854.
    PubMed     Abstract available
    
    
    May 2024
55. FRERICKS N, Kinast V, Steinmann E
    Potential risk of porcine-derived pancreatic enzyme medication for the cross-species transmission of hepatitis E virus.
    Gut. 2024 May 31:gutjnl-2024-332577. doi: 10.1136/gutjnl-2024-332577.
    PubMed    
    
    
    
56. VOGT M, Dudvarski Stankovic N, Cruz Garcia Y, Hofstetter J, et al
    Targeting MYC effector functions in pancreatic cancer by inhibiting the ATPase RUVBL1/2.
    Gut. 2024 May 31:gutjnl-2023-331519. doi: 10.1136/gutjnl-2023-331519.
    PubMed     Abstract available
    
    
    
57. BERKE G, Sahin-Toth M
    Intron-mediated enhancement of SPINK1 expression for pancreatitis therapy.
    Gut. 2024 May 16:gutjnl-2024-332818. doi: 10.1136/gutjnl-2024-332818.
    PubMed    
    
    
    
58. LOPEZ-GIL JC, Garcia-Silva S, Ruiz-Canas L, Navarro D, et al
    The Peptidoglycan Recognition Protein 1 confers immune evasive properties on pancreatic cancer stem cells.
    Gut. 2024 May 16:gutjnl-2023-330995. doi: 10.1136/gutjnl-2023-330995.
    PubMed     Abstract available
    
    
    April 2024
59. THORNTON CS, Waddell BJ, Congly SE, Svishchuk J, et al
    Porcine-derived pancreatic enzyme replacement therapy may be linked to chronic hepatitis E virus infection in cystic fibrosis lung transplant recipients.
    Gut. 2024 Apr 15:gutjnl-2023-330602. doi: 10.1136/gutjnl-2023-330602.
    PubMed     Abstract available
    
    
    
60. 
    Correction: Identification of c-FLIPL and c-FLIPS as critical regulators of death receptor-induced apoptosis in pancreatic cancer cells.
    Gut. 2024;73:e8.
    PubMed    
    
    
    March 2024
61. WANG YC, Mao XT, Sun C, Wang YH, et al
    Pancreas-directed AAV8-hSPINK1 gene therapy safely and effectively protects against pancreatitis in mice.
    Gut. 2024 Mar 29:gutjnl-2023-330788. doi: 10.1136/gutjnl-2023-330788.
    PubMed     Abstract available
    
    
    
62. GUNJAN D, Mahapatra SJ, Garg PK
    Is acute necrotising pancreatitis a chronic disease?
    Gut. 2024 Mar 26:gutjnl-2024-331915. doi: 10.1136/gutjnl-2024-331915.
    PubMed    
    
    
    
63. AMMER-HERRMENAU C, Neesse A
    Response to: short-chain fatty acids in patients with severe acute pancreatitis: friend or foe?
    Gut. 2024 Mar 7:gutjnl-2024-332236. doi: 10.1136/gutjnl-2024-332236.
    PubMed    
    
    
    
64. PUST MM, Rocha Castellanos DM, Rzasa K, Dame A, et al
    Absence of a pancreatic microbiome in intraductal papillary mucinous neoplasm.
    Gut. 2024 Mar 1:gutjnl-2023-331012. doi: 10.1136/gutjnl-2023-331012.
    PubMed     Abstract available
    
    
    February 2024
65. VAN DEN BERG FF, Besselink MG, van Santvoort H
    Short-chain fatty acids in patients with severe acute pancreatitis: friend or foe?
    Gut. 2024 Feb 15:gutjnl-2024-332129. doi: 10.1136/gutjnl-2024-332129.
    PubMed    
    
    
    January 2024
66. HOLLEMANS RA, Timmerhuis HC, Besselink MG, Bouwense SAW, et al
    Long-term follow-up study of necrotising pancreatitis: interventions, complications and quality of life.
    Gut. 2024 Jan 24:gutjnl-2023-329735. doi: 10.1136/gutjnl-2023-329735.
    PubMed     Abstract available
    
    
    
67. TONELLI C, Yordanov GN, Hao Y, Deschenes A, et al
    A mucus production programme promotes classical pancreatic ductal adenocarcinoma.
    Gut. 2024 Jan 23:gutjnl-2023-329839. doi: 10.1136/gutjnl-2023-329839.
    PubMed     Abstract available
    
    
    
68. SABA E, Farhat M, Daoud A, Khashan A, et al
    Oral bacteria accelerate pancreatic cancer development in mice.
    Gut. 2024 Jan 17:gutjnl-2023-330941. doi: 10.1136/gutjnl-2023-330941.
    PubMed     Abstract available
    
    
    
69. KWAN MC, Pitman MB, Fernandez-Del Castillo C, Zhang ML, et al
    Revisiting the performance of cyst fluid carcinoembryonic antigen as a diagnostic marker for pancreatic mucinous cysts: a comprehensive 20-year institutional review.
    Gut. 2024 Jan 9:gutjnl-2023-331138. doi: 10.1136/gutjnl-2023-331138.
    PubMed     Abstract available
    
    
    December 2023
70. AMMER-HERRMENAU C, Antweiler KL, Asendorf T, Beyer G, et al
    Gut microbiota predicts severity and reveals novel metabolic signatures in acute pancreatitis.
    Gut. 2023 Dec 21:gutjnl-2023-330987. doi: 10.1136/gutjnl-2023-330987.
    PubMed     Abstract available
    
    
    
71. BEN-AMI R, Wang QL, Zhang J, Supplee JG, et al
    Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer.
    Gut. 2023 Dec 13:gutjnl-2023-331074. doi: 10.1136/gutjnl-2023-331074.
    PubMed     Abstract available
    
    
    
72. HANNEMANN A, Mayerle J, Beyer G
    Response to: Correspondence on 'Definition of age-dependent reference values for the diameter of the common bile duct and pancreatic duct on MRCP: still needed further discussion' by Wang et al.
    Gut. 2023 Dec 2:gutjnl-2023-331525. doi: 10.1136/gutjnl-2023-331525.
    PubMed    
    
    
    October 2023
73. SANDOR M, Sahin-Toth M
    Functional predictors of pathogenicity of missense CPA1 variants in chronic pancreatitis.
    Gut. 2023 Oct 19:gutjnl-2023-331105. doi: 10.1136/gutjnl-2023-331105.
    PubMed    
    
    
    
74. WANG F, Peng L, Liu Y
    Definition of age-dependent reference values for the diameter of the common bile duct and pancreatic duct on MRCP: still needed further discussion.
    Gut. 2023 Oct 10:gutjnl-2023-331163. doi: 10.1136/gutjnl-2023-331163.
    PubMed    
    
    
    
75. MICHL P, Roth L
    Female advantage in neoadjuvant pancreatic cancer therapy: is it down to macrophages?
    Gut. 2023 Oct 9:gutjnl-2023-330830. doi: 10.1136/gutjnl-2023-330830.
    PubMed    
    
    
    September 2023
76. VAN EIJCK CWF, Mustafa DAM, Vadgama D, de Miranda NFCC, et al
    Enhanced antitumour immunity following neoadjuvant chemoradiotherapy mediates a favourable prognosis in women with resected pancreatic cancer.
    Gut. 2023 Sep 14:gutjnl-2023-330480. doi: 10.1136/gutjnl-2023-330480.
    PubMed     Abstract available
    
    
    
77. WU Y, Seufert I, Al-Shaheri FN, Kurilov R, et al
    DNA-methylation signature accurately differentiates pancreatic cancer from chronic pancreatitis in tissue and plasma.
    Gut. 2023 Sep 14:gutjnl-2023-330155. doi: 10.1136/gutjnl-2023-330155.
    PubMed     Abstract available
    
    
    
78. KARSTENSEN JG, Novovic S, Schmidt PN
    Tailoring treatment to the circumstance: reasoning behind metal versus plastic drainage of pancreatic collections - authors' reply.
    Gut. 2023 Sep 12:gutjnl-2023-330948. doi: 10.1136/gutjnl-2023-330948.
    PubMed    
    
    
    August 2023
79. LIU X, Tang R, Xu J, Tan Z, et al
    CRIP1 fosters MDSC trafficking and resets tumour microenvironment via facilitating NF-kappaB/p65 nuclear translocation in pancreatic ductal adenocarcinoma.
    Gut. 2023 Aug 4:gutjnl-2022-329349. doi: 10.1136/gutjnl-2022-329349.
    PubMed     Abstract available
    
    
    July 2023
80. VANELLA G, Bronswijk M, Van der Merwe SW, Arcidiacono PG, et al
    Tailoring treatment to the circumstance: reasoning behind metal versus plastic drainage of pancreatic collections.
    Gut. 2023 Jul 31:gutjnl-2023-330442. doi: 10.1136/gutjnl-2023-330442.
    PubMed    
    
    
    June 2023
81. BLANCO-GOMEZ A, Jorgensen C
    FAK scaffolds immune escape in pancreatic cancer.
    Gut. 2023 Jun 6:gutjnl-2023-330049. doi: 10.1136/gutjnl-2023-330049.
    PubMed    
    
    
    
82. SAMANTA J, Dhar J
    Plastic is as good as metal: is the 'debris clearance' debate for walled-off necrosis drainage finally over?
    Gut. 2023;72:1223-1224.
    PubMed    
    
    
    May 2023
83. KINKER GS, Vitiello GAF, Diniz AB, Cabral-Piccin MP, et al
    Mature tertiary lymphoid structures are key niches of tumour-specific immune responses in pancreatic ductal adenocarcinomas.
    Gut. 2023 May 25:gutjnl-2022-328697. doi: 10.1136/gutjnl-2022-328697.
    PubMed     Abstract available
    
    
    April 2023
84. ZORNIAK M, Sirtl S, Beyer G, Mahajan UM, et al
    Consensus definition of sludge and microlithiasis as a possible cause of pancreatitis.
    Gut. 2023 Apr 18:gutjnl-2022-327955. doi: 10.1136/gutjnl-2022-327955.
    PubMed     Abstract available
    
    
    
85. BANG JY, Jhala N, Seth A, Krall K, et al
    Standardisation of EUS-guided FNB technique for molecular profiling in pancreatic cancer: results of a randomised trial.
    Gut. 2023 Apr 11:gutjnl-2023-329495. doi: 10.1136/gutjnl-2023-329495.
    PubMed    
    
    
    
86. RAPETTI-MAUSS R, Nigri J, Berenguier C, Finetti P, et al
    SK2 channels set a signalling hub bolstering CAF-triggered tumourigenic processes in pancreatic cancer.
    Gut. 2023;72:722-735.
    PubMed     Abstract available
    
    
    March 2023
87. CANEL M, Slawinska AD, Lonergan DW, Kallor AA, et al
    FAK suppresses antigen processing and presentation to promote immune evasion in pancreatic cancer.
    Gut. 2023 Mar 28:gutjnl-2022-327927. doi: 10.1136/gutjnl-2022-327927.
    PubMed     Abstract available
    
    
    
88. HAMDAN FH, Abdelrahman AM, Kutschat AP, Wang X, et al
    Interactive enhancer hubs (iHUBs) mediate transcriptional reprogramming and adaptive resistance in pancreatic cancer.
    Gut. 2023 Mar 8:gutjnl-2022-328154. doi: 10.1136/gutjnl-2022-328154.
    PubMed     Abstract available
    
    
    February 2023
89. HALLENSLEBEN ND, Stassen PMC, Schepers NJ, Besselink MG, et al
    Patient selection for urgent endoscopic retrograde cholangio-pancreatography by endoscopic ultrasound in predicted severe acute biliary pancreatitis (APEC-2): a multicentre prospective study.
    Gut. 2023 Feb 27:gutjnl-2022-328258. doi: 10.1136/gutjnl-2022-328258.
    PubMed     Abstract available
    
    
    
90. LIU J, Bai W, Zhou T, Xie Y, et al
    SDCBP promotes pancreatic cancer progression by preventing YAP1 from beta-TrCP-mediated proteasomal degradation.
    Gut. 2023 Feb 24:gutjnl-2022-327492. doi: 10.1136/gutjnl-2022-327492.
    PubMed     Abstract available
    
    
    
91. BEYER G, Kasprowicz F, Hannemann A, Aghdassi A, et al
    Definition of age-dependent reference values for the diameter of the common bile duct and pancreatic duct on MRCP: a population-based, cross-sectional cohort study.
    Gut. 2023 Feb 24:gutjnl-2021-326106. doi: 10.1136/gutjnl-2021-326106.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Pancreatitis is free of charge.